Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

Completed · Phase 2 · Has a placebo group

Conditions studied: Alopecia Areata

In brief

The purpose of this study is to evaluate the safety and efficacy of etrasimod monotherapy (2 milligrams \[mg\] and 3 mg) in participants with moderate-to-severe alopecia areata (AA).

Key facts

Study ID
NCT04556734
Run by
Pfizer
People needed
80
Starts
2020-07-29
Expected to finish
2023-06-07
Last updated by the study team
2024-06-26

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.